Stabilized ActRIIB Polypeptides for Protein Manufacturability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapeutic proteins for antagonizing TGF-β family members, such as myostatin and activin, face challenges in manufacturability, making large-scale production inefficient and costly.
Innovation Solution
Development of stabilized human activin receptor IIB (svActRIIB) polypeptides with specific amino acid substitutions at positions 28 and 44, capable of binding and inhibiting activin, GDF-11, and myostatin, and enhanced manufacturability properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic proteins are used to modulate TGF-β family members, then they can bind and inhibit myostatin and activin, but they face challenges in manufacturability and stability during production and purification
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid substitutions at positions 28 and 44 of the ActRIIB polypeptide sequence. These substitutions (such as E28W, S44T) modify the physical and chemical properties of the protein, improving its stability and manufacturability while retaining its ability to bind TGF-β family members. This directly resolves the contradiction by changing the molecular parameters of the therapeutic protein.
2Ease of manufacture
If stabilized ActRIIB polypeptides with amino acid substitutions are developed, then manufacturability and stability are improved, but the complexity of protein engineering increases
Solution Approach 1:
The patent applies local quality by making targeted amino acid substitutions at specific positions (28 and 44) rather than throughout the entire polypeptide sequence. This localized modification approach improves manufacturability and stability without requiring comprehensive redesign of the entire protein structure, thus managing engineering complexity while achieving the desired improvements.
3Manufacturing precision
If uniform glycosylation is achieved through stabilization, then protein consistency and efficacy are improved, but the purification process becomes more challenging
Solution Approach 1:
The amino acid substitutions at positions 28 and 44 modify the glycosylation pattern of the ActRIIB polypeptide, leading to uniform glycosylation. This parameter change in the protein structure standardizes the glycosylation sites, improving batch-to-batch consistency and efficacy while the modified structure also facilitates purification through enhanced stability and reduced aggregation.
Data Source
AI summary
The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.